300705 九典制药
已收盘 09-08 15:00:00
资讯
新帖
简况
九典制药：9月2日召开业绩说明会，投资者参与
证券之星 · 09-07 16:51
九典制药：9月2日召开业绩说明会，投资者参与
九典制药：公司目前有中国药科大学在职员工
证券之星 · 08-28
九典制药：公司目前有中国药科大学在职员工
九典制药（300705）2026年中报简析：净利润同比下降45.21%
证券之星 · 08-23
九典制药（300705）2026年中报简析：净利润同比下降45.21%
九典制药(300705)6月30日股东户数3.04万户，较上期减少11.46%
证券之星 · 08-22
九典制药(300705)6月30日股东户数3.04万户，较上期减少11.46%
图解九典制药中报：第二季度单季净利润同比下降37.86%
证券之星 · 08-22
图解九典制药中报：第二季度单季净利润同比下降37.86%
九典制药：稳住基本盘、创新转型
证券之星 · 08-11
九典制药：稳住基本盘、创新转型
九典制药：中泰证券投资者于8月5日调研我司
证券之星 · 08-05
九典制药：中泰证券投资者于8月5日调研我司
九典制药：关于回购相关安排，现阶段公司暂未披露新的相关计划
证券之星 · 08-05
九典制药：关于回购相关安排，现阶段公司暂未披露新的相关计划
股市必读：九典制药（300705）8月4日董秘有最新回复
证券之星 · 08-05
股市必读：九典制药（300705）8月4日董秘有最新回复
九典制药：公司目前生产经营一切正常，整体发展稳健
证券之星 · 08-04
九典制药：公司目前生产经营一切正常，整体发展稳健
股市必读：九典制药新发布《关于参与国家组织药品集中带量采购拟中选的公告》
证券之星 · 08-04
股市必读：九典制药新发布《关于参与国家组织药品集中带量采购拟中选的公告》
股市必读：九典制药（300705）新发布《关于获得药品注册证书的公告》
证券之星 · 07-31
股市必读：九典制药（300705）新发布《关于获得药品注册证书的公告》
九典制药最新公告：中药1.1类创新药椒七止痛凝胶贴膏获批上市
证券之星 · 07-29
九典制药最新公告：中药1.1类创新药椒七止痛凝胶贴膏获批上市
股市必读：九典制药（300705）7月28日董秘有最新回复
证券之星 · 07-29
股市必读：九典制药（300705）7月28日董秘有最新回复
九典制药：公司及子公司目前共有56个品种、65个品规进入2026版国家基本药物目录
证券之星 · 07-28
九典制药：公司及子公司目前共有56个品种、65个品规进入2026版国家基本药物目录
【机构调研记录】东方基金调研九典制药
证券之星 · 07-27
【机构调研记录】东方基金调研九典制药
股市必读：九典制药（300705）7月24日披露最新机构调研信息
证券之星 · 07-27
股市必读：九典制药（300705）7月24日披露最新机构调研信息
九典制药：湖南医药发展私募基金、光证资管等多家机构于7月23日调研我司
证券之星 · 07-24
九典制药：湖南医药发展私募基金、光证资管等多家机构于7月23日调研我司
九典制药：贵山私募、江苏恒汇泰私募等多家机构于7月6日调研我司
证券之星 · 07-07
九典制药：贵山私募、江苏恒汇泰私募等多家机构于7月6日调研我司
九典制药最新公告：获得西尼地平片及氨溴特罗口服溶液药品注册证书
证券之星 · 07-01
九典制药最新公告：获得西尼地平片及氨溴特罗口服溶液药品注册证书
加载更多
公司概况
公司名称：
湖南九典制药股份有限公司
所属行业：
医药制造业
上市日期：
2017-10-10
主营业务：
湖南九典制药股份有限公司的主营业务是化药制剂、原料药、药用辅料、中药、大健康产品的研发、生产、销售，以及药品零售、医药CXO服务、养生保健服务等。公司的主要产品是药品制剂、原料药、药用辅料。公司荣获“国家级绿色工厂”“长沙市示范性水载体”“湖南省绿色工厂”“环保示范企业”“环境保护先进单位”等荣誉。
发行价格：
10.37
{"stockData":{"symbol":"300705","market":"SZ","secType":"STK","nameCN":"九典制药","latestPrice":11.15,"timestamp":1788851016000,"preClose":11.03,"halted":0,"volume":4780976,"delay":0,"changeRate":0.0109,"floatShares":370000000,"shares":500000000,"eps":0.6818,"marketStatus":"已收盘","change":0.12,"latestTime":"09-08 15:00:00","open":11,"high":11.18,"low":10.98,"amount":52958900,"amplitude":0.0181,"askPrice":11.16,"askSize":482,"bidPrice":11.15,"bidSize":88,"shortable":0,"etf":0,"ttmEps":0.6818,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788917400000},"marketStatusCode":5,"adr":0,"adjPreClose":11.03,"symbolType":"stock","openAndCloseTimeList":[[1788831000000,1788838200000],[1788843600000,1788850800000]],"highLimit":12.13,"lowLimit":9.93,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":500291194,"isCdr":false,"pbRate":2.16,"roa":"--","peRate":16.353769,"roe":"5.94%","epsLYR":0.96,"committee":-0.438976,"marketValue":5578000000,"turnoverRate":0.0129,"status":0,"floatMarketCap":4125000000},"requestUrl":"/m/hq/s/300705","defaultTab":"news","newsList":[{"id":"2665196623","title":"九典制药：9月2日召开业绩说明会，投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2665196623","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665196623?lang=zh_cn&edition=full","pubTime":"2026-09-07 16:51","pubTimestamp":1788771085,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年9月2日九典制药发布公告称公司于2026年9月2日召开业绩说明会。尊敬的投资者您好，可转债的转股价格调整、售、赎等均有明确的条款约定，公司会严格按照《募集说明书》及相关法律法规执行。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700021459.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662531120","title":"九典制药：公司目前有中国药科大学在职员工","url":"https://stock-news.laohu8.com/highlight/detail?id=2662531120","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662531120?lang=zh_cn&edition=full","pubTime":"2026-08-28 11:37","pubTimestamp":1787888246,"startTime":"0","endTime":"0","summary":"证券之星消息，九典制药(300705)08月28日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司有考虑引进首都医科大，北大医学院，浙大医学院，中国药科大学，京都大学医药研究，名校等毕业的优秀人才吗？谢谢九典制药回复：尊敬的投资者您好，公司目前有中国药科大学在职员工，其他您提及的院校暂未招录过，后续公司将根据业务发展需要，持续关注和引进各类优秀人才。感谢您对公司的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800024087.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661212685","title":"九典制药（300705）2026年中报简析：净利润同比下降45.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661212685","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661212685?lang=zh_cn&edition=full","pubTime":"2026-08-23 06:15","pubTimestamp":1787436946,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期九典制药发布2026年中报。根据财报显示，九典制药净利润同比下降45.21%。截至本报告期末，公司营业总收入12.87亿元，同比下降14.89%，归母净利润1.6亿元，同比下降45.21%。按单季度数据看，第二季度营业总收入6.92亿元，同比下降15.24%，第二季度归母净利润1.03亿元，同比下降37.86%。去年的净利率为15.11%，算上全部成本后，公司产品或服务的附加值高。本文数据来源于九典制药2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300002050.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661216736","title":"九典制药(300705)6月30日股东户数3.04万户，较上期减少11.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661216736","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661216736?lang=zh_cn&edition=full","pubTime":"2026-08-22 17:09","pubTimestamp":1787389791,"startTime":"0","endTime":"0","summary":"证券之星消息，近日九典制药披露，截至2026年6月30日公司股东户数为3.04万户，较3月31日减少3936.0户，减幅为11.46%。在化学制药行业个股中，九典制药股东户数低于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.67万户。从股价来看，2026年3月31日至2026年6月30日，九典制药区间跌幅为26.92%，在此期间股东户数减少3936.0户，减幅为11.46%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082200015095.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661920294","title":"图解九典制药中报：第二季度单季净利润同比下降37.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661920294","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661920294?lang=zh_cn&edition=full","pubTime":"2026-08-22 01:24","pubTimestamp":1787333076,"startTime":"0","endTime":"0","summary":"证券之星消息，九典制药2026年中报显示，上半年度公司主营收入12.87亿元，同比下降14.89%；归母净利润1.6亿元，同比下降45.21%；扣非净利润1.49亿元，同比下降47.29%；其中2026年第二季度，公司单季度主营收入6.92亿元，同比下降15.24%；单季度归母净利润1.03亿元，同比下降37.86%；单季度扣非净利润9844.41万元，同比下降38.13%；负债率34.23%，投资收益-127.15万元，财务费用1460.46万元，毛利率64.26%。财报数据概要请见下图:本文数据来源于九典制药2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082200001768.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658699859","title":"九典制药：稳住基本盘、创新转型","url":"https://stock-news.laohu8.com/highlight/detail?id=2658699859","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658699859?lang=zh_cn&edition=full","pubTime":"2026-08-11 11:36","pubTimestamp":1786419407,"startTime":"0","endTime":"0","summary":"谢谢九典制药回复：尊敬的投资者您好，公司正通过“稳住基本盘、创新转型”双轮驱动来改善和提升经营效益，从经皮外用制剂、口服制剂、原料药和药用辅料、研发创新等多维度协同发力，营销端同步深耕院内与院外市场。院内市场方面，公司将稳固集采落地后核心品种的销售基本盘，保障洛索洛芬钠凝胶贴膏院内市场稳定放量，同时加大对酮洛芬凝胶贴膏、代温灸膏等特色品种的学术推广与市场渗透力度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100014912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657547933","title":"九典制药：中泰证券投资者于8月5日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2657547933","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657547933?lang=zh_cn&edition=full","pubTime":"2026-08-05 21:01","pubTimestamp":1785934906,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年8月5日九典制药发布公告称中泰证券于2026年8月5日调研我司。该产品将丰富公司产品线，预计将对公司业绩产生积极影响。公司已将代温灸膏列为重点推广品种，前期已投入大量品牌推广资源，全力提升产品市场知名度与渗透率。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500041691.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0276","600918","300705"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657498542","title":"九典制药：关于回购相关安排，现阶段公司暂未披露新的相关计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2657498542","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657498542?lang=zh_cn&edition=full","pubTime":"2026-08-05 20:48","pubTimestamp":1785934115,"startTime":"0","endTime":"0","summary":"证券之星消息，九典制药(300705)08月05日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司股价这么低，有考虑增持回购计划吗？谢谢九典制药回复：尊敬的投资者您好，关于回购相关安排，现阶段公司暂未披露新的相关计划。若后续公司筹划新的股份回购安排，将严格按照法律法规要求，及时履行信息披露义务。感谢您对公司的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500041205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657565606","title":"股市必读：九典制药（300705）8月4日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2657565606","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657565606?lang=zh_cn&edition=full","pubTime":"2026-08-05 02:46","pubTimestamp":1785869172,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘，九典制药报收于11.13元，上涨0.72%，换手率1.83%，成交量6.76万手，成交额7539.34万元。董秘最新回复投资者： 请问贵公司现在整体发展如何？在行业内属于中上等还是中下等呢？当日关注点交易信息汇总：8月4日主力资金净流入160.34万元，占总成交额2.13%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500002316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656538147","title":"九典制药：公司目前生产经营一切正常，整体发展稳健","url":"https://stock-news.laohu8.com/highlight/detail?id=2656538147","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656538147?lang=zh_cn&edition=full","pubTime":"2026-08-04 15:04","pubTimestamp":1785827057,"startTime":"0","endTime":"0","summary":"证券之星消息，九典制药(300705)08月04日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司现在整体发展如何？在行业内属于中上等还是中下等呢？谢谢九典制药回复：尊敬的投资者您好，公司目前生产经营一切正常，整体发展稳健。感谢您对公司的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400020082.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656305724","title":"股市必读：九典制药新发布《关于参与国家组织药品集中带量采购拟中选的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656305724","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656305724?lang=zh_cn&edition=full","pubTime":"2026-08-04 02:07","pubTimestamp":1785780430,"startTime":"0","endTime":"0","summary":"截至2026年8月3日收盘，九典制药报收于11.05元，上涨0.36%，换手率1.15%，成交量4.25万手，成交额4683.59万元。公司公告汇总关于参与国家组织药品集中带量采购拟中选的公告湖南九典制药股份有限公司于2026年7月31日参加第12批国家组织药品集中带量采购投标，公司产品琥珀酸亚铁片和吲哚布芬片拟中选。琥珀酸亚铁片拟中选价格为9.68元，约定采购量为3,819.3301万片；吲哚布芬片拟中选价格为27.56元，约定采购量为68.4346万片，供应省份均为全国。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400001564.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655077038","title":"股市必读：九典制药（300705）新发布《关于获得药品注册证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2655077038","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655077038?lang=zh_cn&edition=full","pubTime":"2026-07-31 02:05","pubTimestamp":1785434717,"startTime":"0","endTime":"0","summary":"截至2026年7月30日收盘，九典制药报收于10.9元，上涨1.87%，换手率2.48%，成交量9.18万手，成交额1.01亿元。当日关注点交易信息汇总：7月30日主力资金净流入295.01万元，占总成交额2.93%。公司公告汇总：九典制药获批椒七止痛凝胶贴膏《药品注册证书》，为国内首家，注册分类为中药1.1类，适应症为膝骨关节炎寒凝血瘀证。公司为国内首家取得该品种药品注册证书的企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100001521.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655895635","title":"九典制药最新公告：中药1.1类创新药椒七止痛凝胶贴膏获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2655895635","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655895635?lang=zh_cn&edition=full","pubTime":"2026-07-29 21:20","pubTimestamp":1785331201,"startTime":"0","endTime":"0","summary":"九典制药(300705.SZ)公告称，公司从国家药监局网站获悉，药监局已批准公司申报的中药1.1类创新药椒七止痛凝胶贴膏上市。该药品为中药复方外用制剂，用于膝骨关节炎寒凝血瘀证，为患者提供新的治疗选择。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072900039258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","159992","BK0239","300705","06978","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655884912","title":"股市必读：九典制药（300705）7月28日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2655884912","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655884912?lang=zh_cn&edition=full","pubTime":"2026-07-29 02:21","pubTimestamp":1785262871,"startTime":"0","endTime":"0","summary":"截至2026年7月28日收盘，九典制药报收于10.53元，上涨0.1%，换手率1.18%，成交量4.37万手，成交额4607.84万元。感谢回复董秘： 尊敬的投资者您好，公司及子公司目前共有56个品种、65个品规进入2026版国家基本药物目录。交易信息汇总资金流向7月28日主力资金净流入100.25万元，占总成交额0.0%；游资资金净流出489.88万元，占总成交额0.0%；散户资金净流入389.63万元，占总成交额0.0%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072900001471.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654007229","title":"九典制药：公司及子公司目前共有56个品种、65个品规进入2026版国家基本药物目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2654007229","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654007229?lang=zh_cn&edition=full","pubTime":"2026-07-28 16:33","pubTimestamp":1785227590,"startTime":"0","endTime":"0","summary":"证券之星消息，九典制药(300705)07月28日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好，请问： 公司本次一共有多少个药品纳入2026 版国家基本药物目录？ JIJ02 痤疮凝胶何时启动二期？感谢回复九典制药回复：尊敬的投资者您好，公司及子公司目前共有56个品种、65个品规进入2026版国家基本药物目录。JIJ02凝胶目前暂未进入临床二期阶段，公司将稳步推进在研产品研发进程，感谢您对公司的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800026278.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654306026","title":"【机构调研记录】东方基金调研九典制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2654306026","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654306026?lang=zh_cn&edition=full","pubTime":"2026-07-27 08:01","pubTimestamp":1785110471,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及7月24日披露的机构调研信息，东方基金近期对1家上市公司进行了调研，相关名单如下：1）九典制药 调研纪要：洛索洛芬钠凝胶贴膏集采后价格大幅下调，销量增长明显，但收入预计下滑，短期难以以量补价。2023至2025年外用贴膏剂市场复合增速10.27%，受益于老龄化、慢性疼痛人群增加及居家理疗消费兴起。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700001631.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654064136","title":"股市必读：九典制药（300705）7月24日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2654064136","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654064136?lang=zh_cn&edition=full","pubTime":"2026-07-27 02:16","pubTimestamp":1785089773,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，九典制药报收于10.15元，下跌4.87%，换手率2.02%，成交量7.46万手，成交额7716.3万元。机构调研要点：代温灸膏为公司中药独家OTC甲类产品，2025年终端销售额达1.66亿元，已被列为重点推广品种及今年重点培育增长品类。机构调研要点7月23日特定对象调研洛索洛芬钠凝胶贴膏集采落地后价格大幅下调，上半年院内销量明显增长，全年销量预期保持增长；收入端受价格影响将有所回落，短期内难以完全实现以量补价。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700001078.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653083405","title":"九典制药：湖南医药发展私募基金、光证资管等多家机构于7月23日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2653083405","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653083405?lang=zh_cn&edition=full","pubTime":"2026-07-24 17:49","pubTimestamp":1784886585,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年7月24日九典制药发布公告称湖南医药发展私募基金、光证资管、鑫巢资本、前海人寿、天风证券、东方基金于2026年7月23日调研我司。全年来看，销量预期保持增长态势。公司已将代温灸膏列为重点推广品种，前期已投入大量品牌推广资源，全力提升产品市场知名度与渗透率。摩熵医药的数据显示，2023 至 2025 年国内外用贴膏剂市场复合增速为 10.27%，整体市场增长态势稳健。九典制药主营业务：医药产品的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400031356.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","300705","159938","BK1515","BK0239","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649608974","title":"九典制药：贵山私募、江苏恒汇泰私募等多家机构于7月6日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2649608974","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649608974?lang=zh_cn&edition=full","pubTime":"2026-07-07 09:31","pubTimestamp":1783387863,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年7月6日九典制药发布公告称贵山私募、江苏恒汇泰私募、上海牛福私募、广东天运资产、广州中天智诚、深圳德泉资本、深圳富安基金、投资者于2026年7月6日调研我司。该产品自上市以来销量逐年增加，公司对其市场前景持乐观态度。九典制药主营业务：医药产品的研发、生产和销售。该股最近90天内共有1家机构给出评级，买入评级1家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700008835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648151296","title":"九典制药最新公告：获得西尼地平片及氨溴特罗口服溶液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2648151296","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648151296?lang=zh_cn&edition=full","pubTime":"2026-07-01 18:41","pubTimestamp":1782902468,"startTime":"0","endTime":"0","summary":"九典制药(300705.SZ)公告称，公司近日收到国家药监局下发的《药品注册证书》，涉及西尼地平片(规格10mg)和氨溴特罗口服溶液(规格100ml)两个药品。西尼地平片适用症是用于高血压患者的治疗，截至本公告日，西尼地平片国内共有4家企业取得了药品注册证书，公司为国内第1家通过或视同通过仿制药质量和疗效一致性评价的企业；氨溴特罗口服溶液常用于治疗急、慢性呼吸道疾病（如急、慢性支气管炎、肺气肿等）引起的咳嗽、痰液黏稠、排痰困难、喘息等。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100036224.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788879929330,"stockEarnings":[{"period":"1week","weight":-0.0009},{"period":"1month","weight":-0.0282},{"period":"3month","weight":0.0318},{"period":"6month","weight":-0.2327},{"period":"1year","weight":-0.3701},{"period":"ytd","weight":-0.2389}],"compareEarnings":[{"period":"1week","weight":-0.0134},{"period":"1month","weight":-0.0019},{"period":"3month","weight":-0.0193},{"period":"6month","weight":-0.0486},{"period":"1year","weight":0.0315},{"period":"ytd","weight":-0.0091}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖南九典制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"30409人(较上一季度减少11.46%)","perCapita":"12165股","listingDate":"2017-10-10","address":"湖南省长沙市浏阳市经济技术开发区健康大道1号","registeredCapital":"50029万元","survey":" 湖南九典制药股份有限公司的主营业务是化药制剂、原料药、药用辅料、中药、大健康产品的研发、生产、销售，以及药品零售、医药CXO服务、养生保健服务等。公司的主要产品是药品制剂、原料药、药用辅料。公司荣获“国家级绿色工厂”“长沙市示范性水载体”“湖南省绿色工厂”“环保示范企业”“环境保护先进单位”等荣誉。","listedPrice":10.37},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"九典制药(300705)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供九典制药(300705)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"九典制药,300705,九典制药股票,九典制药股票老虎,九典制药股票老虎国际,九典制药行情,九典制药股票行情,九典制药股价,九典制药股市,九典制药股票价格,九典制药股票交易,九典制药股票购买,九典制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"九典制药(300705)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供九典制药(300705)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}